NCT06668181 is a Phase 3 clinical trial of Bimekizumab in Enthesitis-related Arthritis, sponsored by UCB Biopharma SRL.

Who is sponsoring NCT06668181?

NCT06668181 is sponsored by UCB Biopharma SRL.

What drugs are being tested in NCT06668181?

Interventions in NCT06668181: Bimekizumab.

What condition does NCT06668181 study?

NCT06668181 studies Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis.

Is NCT06668181 still recruiting?

NCT06668181 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT06668181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting now Phase 3 Last updated 27 February 2026

What this trial tests

Phase 3 trial testing Bimekizumab in Enthesitis-related Arthritis in 40 participants. Currently enrolling.

Timeline

11 March 2025

Primary endpoint
12 April 2028

31 July 2030

Quick facts

Lead sponsor	UCB Biopharma SRL
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	11 March 2025
Primary completion	12 April 2028
Estimated completion	31 July 2030
Sites	23 locations across France, United Kingdom, Germany, Poland, Canada, Spain

Drugs / interventions tested

Bimekizumab (BIMEKIZUMAB) — full drug profile →

Conditions studied

Enthesitis-related Arthritis — all drugs for Enthesitis-related Arthritis →
Juvenile Psoriatic Arthritis — all drugs for Juvenile Psoriatic Arthritis →

Sponsor

UCB Biopharma SRL — full company profile →

Who can join

Adults 2 to 18, any sex, with Enthesitis-related Arthritis or Juvenile Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bimekizumab

Trials testing the same drug.

NCT07497620 — Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP · Phase 4 · not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07219420 — A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis · Phase 3 · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
NCT06742333 — Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? · Phase 2 · recruiting

Other UCB Biopharma SRL trials

Trials by the same sponsor.

NCT07465289 — A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gr · Phase 3 · not yet recruiting
NCT07463521 — A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis · Phase 3 · not yet recruiting
NCT07277660 — A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Stu · Phase 2 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT07286682 — A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06668181 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Biopharma SRL
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing